







David Bundred, Non Executive Chairman

David has industrial experience at senior management levels in the UK, Germany and the US and is now an active investor with "a hands on" focus in a small number of high growth companies. He previously had a 24 year long career until 1999 at Lucas, which included positions as General Manager of the Lucas Brake Controls and Lucas Truck Brake Divisions and his last appointment was that of Chief Operating Officer of the worldwide business of Lucas Aerospace. Between 2003 and 2005 he was CEO of TMD Friction Group, a large private German industrial group which is one of the world's leading brake pad system suppliers for the automotive industry.



Dr Kevin Johnson, Chief Executive Officer

Kevin has a doctorate in Chemistry from the University of Liverpool and an MBA from Manchester Business School. He has spent six years in product development for the chemical industry and has a broad experience with OEM multinationals in the area of new technology development. Previously he worked for Avecia, formerly AstraZeneca.



Michael Cunningham, Chief Financial Officer

Michael is a Fellow of the Association of Chartered Certified Accountants, holds an MBA from the European School of Management and Technology in Berlin and a Bachelor of Engineering degree from Queens University Belfast. Michael joins the Company from Bentley Motors Ltd where he was Profitability Controller, and previously Senior Finance Manager (Mulliner), reporting into the Company CFO. Prior to joining Bentley, Michael was Finance Director of Aquila Truck Centres Ltd; Commercial Director (initially Regional Financial Controller) of MAN Truck and Bus UK, and Financial Controller of Preston Group, a family owned car dealership.

98 PROJECT SPARK

- Proposed £20m fundraise:
 - £13m manufacturing capex
 - £5m growth working capital
 - £2m open offer proceeds
- To support expected contract awards from existing and new OEM customers

About Surface Transforms

- Carbon ceramic brake disks are suitable for high performance vehicles
- One of only two mainstream carbon ceramic brake disc companies in the world
- Customers include major automotive OEMs:
 - ICE and EV
 - UK, US and Europe

New contract awards in last 18 months

- 4 OEMs contracts valued at £43m[†]
- Includes a £27.5m contract in Sept 2020 with new OEM customer

Manufacturing capacity

- £20m/yr revenue manufacturing capacity available Q2 2021
- Fundraise to build revenue manufacturing capacity to £35m/yr in 2022



Brakes used to slow and stop the vehicle

Activated by the driver's foot







Braking achieved by the caliper pressing the brake pads against the brake disc



- Brake components installed on all four wheels of the car
- Key safety and performance feature of the vehicle



Automotive market drivers

Compelling drivers are growing the use of carbon ceramic (CC) brakes





No corrosion Cleaner wheels

- weight reduction with opportunity on the chassis to increase the saving to 100kg

Competition



- Monopolist supplier
- Revenues circa



ST – OEM customers



- Engaged with significant number of OEMs
- **™** Contracts with 5 OEMs

OEM 1	British performance car manufacturer
OEM 3 (covers 2 & 4)	German group with performance car manufacturer as lead
OEM 5	German car manufacturer
OEM 6	British performance car manufacturer
OEM 7	Swedish performance car manufacturer
OEM 8	Global car manufacturer
OEM 9	New car manufacturer
New OEM	German car manufacturer
New OEM	USA car manufacturer
New OEM	European car manufacturer


Customer & shareholder value



Shareholder value &

Investment proposition

Strategy - be a world class, profitable manufacturing and engineering company of CC brakes



^{£30}m/Y 2024 prospective £7m/Y capacity requirement Multi year contracts generating strong growth ry 22 . operating profit Contracts valued at f43m from 4 OFMs in last 18 months t Expected customer demand exceeds installed capacity * Source - SMMT car sales data & ST pricing data † This is based on the directors' expectations and their understanding of the relevant OEM's production plan and estimated demand for discs

The figures shown in the graph are based on the directors' expectations following conversations with the OEMs, their understanding of the OEMs' production plans and estimated demand for discs

ST manufacturing facilities & capacity capability



Office Space

(SVP) Small Volume Production

OEM cell 1

Additional OEM cells


13,000 ft²


5,000 ft²


7,000 ft²

30,000 ft²

55,000 ft² facility








- Capacity planning assumptions
 - Customer capacity agreed as part of contract award
 - Time between contract award and SOP longer than building and demonstrating manufacturing capacity
- ♠ OEM 1-7 work to this principle
 - Timeline between contract award and SOP circa 2 years
- Building and demonstrating production capacity circa 18 months

Disruptive OEM 8 & 9*



Disruptive OEM behaviour

- Minimise future engineering costs & time by 'carrying over' approved parts to new models
- Compress timeline between contract award and SOP reduced to circa 12-15 months
- Customer requirement capacity will be available to their timeline



- 2020 contract award followed this compressed timeline ST had capacity available
- IMPACT carry over models represent demand beyond current ST production capacity

OEM 9

- New entrant OEM with compressed timing plan prior to contract award
- IMPACT OEM 9 demand beyond current ST production capacity

^{*} Assumes OEM 8 carry over 2nd and 3rd models, OEM 9 becomes firm contract and is based on director's expectations for SOP and their understanding of the relevant OEM's production plan and estimated demand for discs

ST capacity requirements

Current contracts, carry over & OEM 9



	2021	2022	2023	2024
ASTON MARTIN	Valkyrie			
<u>Koenigsegg</u>	Jesko	Gemera		
OEM 5		1 st Model		2 nd & 3 rd Model
OEM 8	1 st Model		2 nd Model 3 rd Model	
OEM 9		1st & 2nd Models		




* Assumes OEM 8 carry over 2nd and 3rd models, OEM 9 becomes firm contract and is based on director's expectations for SOP and their understanding of the relevant OEM's production plan and estimated demand for discs

2024 capacity – prospective contract pipeline



	2021	2022	2023	2024	2025	2026
OEM 6						
OEM 1						
OEM 3 (covering OEM 4)						
New OEM customer						
New OEM customer						
New OEM customer						




Prospective contract pipeline has potential to fill current facility by 2024

Capacity plan – OEM Cell 2



- Delivers required £35m/yr capacity revenue during 2022
- ⊕ OEM Cell 2 available for customer "off tool off process" end of '22/23
- ♠ Payback circa 15 months (at full capacity)



Fundraise – use of proceeds

Build capacity and support revenue growth



	Investment £m
Manufacturing capacity (Cell 1)	0.7
Manufacturing capacity (Cell 2)	9.2
Manufacturing resilience & development equipment	3.1
Capital expenditure (capacity & resilience)	13
Working capital (supporting rapid revenue growth)	5
Placing & subscriptions*	18
Proposed open offer (balance sheet strength & headroom)	2
TOTAL proceeds	20

Tue 19th Jan

Record date of Open offer

11:00am Fri 5th Feb

Close, payment & settlement

Mon 8th Feb

Result of Open offer RNS

Wed 17th Feb

Dispatch of certificates



Trading update



- Revenues in line with expectations at £2m
- € Cash £1.1m with £0.6m R&D tax credit in 2021 and borrowing of £0.5m
- OEM contracts progressing to plan
- ⊙EM Cell 1 capacity on track for OEM series supply in 2021

Investment summary



- Multiyear recurring OEM contracts in place
 - Contracts valued at £43m from 4 OEMs in last 18 months
 - Growing revenues with good margins leading to profitability and positive EBIT
 - Prospective project pipeline in excess of £75m/yr within the next 5 years
- Trading in line with expectations
- Business planning based on two scenarios
 - Commercial risks to additional revenues and additional profitability
 - Customer demand requirements for manufacturing capabilities and capacity
- Capital investment required
 - Support demand from customer contracts including carry over projects and OEM 9
 - Manage manufacturing capacity risk and timeline
 - Payback circa 15 months (at full capacity)

Disclaimer



The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the "Presentation") have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate Surface Transforms plc ("ST" or the "Company"). This Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of definitive documentation in final form (which may contain different information from the information contained in this Presentation), and you own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.

By accepting this Presentation you confirm, represent and warrant that you have consented to receive inside information (as defined in the Criminal Justice Act 1993 and the Financial Services and Markets Act 2000 (as amended)), and you agree not to deal in any securities of the Company until such time as such inside information has been made public and until such time that the Placing has been publicly announced by the Company.

This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are confidential and are subject to updating, completion, revision, further verification and amendment without notice.

The Presentation is being distributed on request only to, and is directed at, authorised persons or exempt persons within the meaning of FSMA or any order made thereunder or to those persons falling within the following articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Financial Promotion Order"); Investment Professionals (as defined in Article 19(5)) or are eligible counterparties within the meaning given in COBS 3.6.1 of the FSA Handbook as at 1 November 2007; High Net Worth Companies (as defined in Article 49(2)) and Members or Creditors of the Company (as defined in Article 43(2)) as well as persons to who distribution may otherwise lawfully be made (all such persons being "Relevant Persons"). Any person who is not a Relevant Person should not rely on this Presentation nor take any action upon it but should return it immediately to the Company.

This Presentation is exempt from the general restriction in section 21 of FSMA relating to the communication of invitations or inducements to engage in investment activity on the grounds that it is made only to certain categories of persons.

Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the "US"), Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship.

The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements are identified by the use of such terms as uncertainties and uncertainties are uncertainties and uncertainties are incorrect. The company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (iii) you have read and agree to comply with the contents of this disclaimer.